Drug news
CHMP recommends extension of Isentress indication for HIV
The CHMP has recommended a change to the indication for Isentress (raltegravir), from Merck., which is now indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adults, adolescents, and children from the age of 2 years.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.